PTPI Stock Chart & Stats
$0.01
-$0.06(-14.22%)
At close: 4:00 PM EST
$0.01
-$0.06(-14.22%)
Day’s Range― - ―
52-Week Range$0.01 - $16.25
Previous CloseN/A
Volume1.29M
Average Volume (3M)352.83K
Market Cap
$183.05K
Enterprise Value-$4.17M
Total Cash (Recent Filing)$4.35M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta1.26
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding42,372,260
10 Day Avg. Volume348,620
30 Day Avg. Volume352,829
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.78
Price to Sales (P/S)0.00
P/FCF Ratio-0.33
Enterprise Value/Market Cap-22.76
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda1.16
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusModerate Buy
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
App Study ResultsPetros announced positive results from a small app comprehension study finding the vast majority of subjects understood the communication and messages from Petros’ App for self-selecting over-the-counter (OTC) Stendra.
Regulatory PathwayThe finalized ACNU pathway should further de-risk development and provide greater clarity in terms of regulatory standards, study designs and costs for development.
Bears Say
Strategic Shift ImpactThe strategic focus on platform technology is seen as a move away from biotechnology/pharmaceuticals development, impacting previous market expectations.
Petros Pharmaceuticals News
PTPI FAQ
What was Petros Pharmaceuticals’s price range in the past 12 months?
Petros Pharmaceuticals lowest stock price was $0.01 and its highest was $16.25 in the past 12 months.
What is Petros Pharmaceuticals’s market cap?
Petros Pharmaceuticals’s market cap is $183.05K.
When is Petros Pharmaceuticals’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Petros Pharmaceuticals’s earnings last quarter?
Currently, no data Available
Is Petros Pharmaceuticals overvalued?
According to Wall Street analysts Petros Pharmaceuticals’s price is currently Overvalued.
Does Petros Pharmaceuticals pay dividends?
Petros Pharmaceuticals does not currently pay dividends.
What is Petros Pharmaceuticals’s EPS estimate?
Petros Pharmaceuticals’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Petros Pharmaceuticals have?
Petros Pharmaceuticals has 42,372,260 shares outstanding.
What happened to Petros Pharmaceuticals’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Petros Pharmaceuticals?
Currently, no hedge funds are holding shares in PTPI
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Petros Pharmaceuticals
Petros Pharmaceuticals, Inc. is a pharmaceutical company dedicated to male health solutions. Their activities include both the commercialization and ongoing development of Stendra, a prescription PDE-5 inhibitor specifically designed for treating erectile dysfunction (ED). Furthermore, Petros is advancing H100, a proprietary topical formulation currently in development as a potential treatment for acute Peyronie's disease. The company's offerings also extend to a range of erectile dysfunction products, such as vacuum erection devices. Petros Pharmaceuticals, Inc. operates from its base in New York, New York.
Technical Analysis
China Pharma Holdings
―
Sonoma Pharmaceuticals
―
―
PainReform
―
Shuttle Pharmaceuticals Holdings, Inc.
―
Ownership Overview
Options Prices
Currently, No data available
---